Efficacy of Topical Recombinant Human Platelet-Derived Growth Factor for Treatment of Diabetic Lower-Extremity Ulcers: Systematic Review and Meta-Analysis

Xiaohong Zhao,Haifeng Gu,Zhu-An Xu,Qin Zhang,Xueying Lv,Xiaojun Zheng,Yunmei Yang

DOI: https://doi.org/10.1016/j.metabol.2014.06.005

2014-01-01

Abstract:Objective Recombinant human platelet-derived growth factor (rhPDGF) is used topically in the treatment of diabetic lower-extremity ulcers. There have been few meta-analyses of the efficacy of rhPDGF in this treatment context. The aim of this study was to perform an updated systematic review and meta-analysis to assess the clinical efficacy of rhPDGF in the treatment of diabetic lower-extremity ulcers. Methods We searched the MEDLINE, Cochrane Library, EMBASE and Web of Knowledge databases up to April 30, 2014. Studies were identified and selected, and data were extracted by two independent reviewers. The primary efficacy outcome was complete healing rate. Adverse events were also assessed. The studies were evaluated for quality and publication bias. Results A total of 6 randomized controlled trials including 992 patients were selected from 173 identified studies. The studies compared rhPDGF treatment in the context of standard of care (SOC) to placebo or SOC alone. In the absence of study heterogeneity, a fixed-effects model was performed, and the combined odds ratio (OR) indicated a significantly greater complete healing rate in patients treated with rhPDGF compared to placebo or SOC alone. The ORs ranged from 0.58 to 2.77, with a combined OR of 1.53 (95% CI = 1.14 to 2.04, p = 0.004). A sensitivity analysis (leave-one-out method) indicated good study reliability, and a funnel plot with Egger test showed no publication bias. Conclusion These results indicate that rhPDGF is efficacious in the treatment of diabetic lower-extremity ulcers.